- Visibility 220 Views
- Downloads 197 Downloads
- Permissions
- DOI 10.18231/j.ijmr.51975.1758360042
-
CrossMark
Clinico-mycological profile and antifungal susceptibility patterns of zygomycosis during the COVID-19 pandemic at a tertiary care center
- Author Details:
-
Sinduja Subramaniyan *
-
Anupma Jyoti Kindo
-
Prasanna Kumar Saravanam
Sinduja Subramaniyan *
Background: Zygomycosis has emerged as a significant opportunistic fungal infection, with a marked increase in incidence during the COVID-19 pandemic, particularly among immunocompromised individuals such as those with diabetes mellitus.
Aim: To analyze the clinico-mycological profile of zygomycosis and determine the antifungal susceptibility patterns, including the minimum inhibitory concentrations (MICs) of commonly used antifungal agents.
Materials and Methods: A total of 57 culture-positive clinical isolates suspected of zygomycosis were included. Specimens were collected from paranasal sinuses, bronchoalveolar lavage, bronchial wash, wounds, nasal swabs, and lung and brain tissues. Identification was done via culture, microscopy, and gene sequencing. Antifungal susceptibility testing for itraconazole, posaconazole, voriconazole, and amphotericin B was performed using the CLSI M38-A2 broth microdilution method.
Results: Rhizopus spp. was the predominant isolate (83%), followed by Apophysomyces variabilis (7%), Lichtheimia corymbifera (7%), and Cunninghamella bertholletiae (2%). Amphotericin B showed the highest efficacy among the studied antifungal agents, followed by posaconazole. Itraconazole and voriconazole was largely ineffective.
Conclusion: Zygomycosis continues to be a life-threatening infection, especially in patients with diabetes and a history of COVID-19. Rhizopus spp. remains the most common etiological agent. Amphotericin B and posaconazole are the antifungal agents deemed most likely to be effective, underlining the importance of routine susceptibility testing for optimized treatment outcomes.
References
- Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, et al. Mucormycosis: an opportunistic pathogen during COVID-19. Environ Res. 2021;201:111643.
- Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25(4):215–29.
- Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses. 2021;64(8):798–808.
- Khanna M, Challa S, Kabeil AS, Inyang B, Gondal FJ, Abah GA, et al. Risk of mucormycosis in diabetes mellitus: a systematic review. Cureus. 2021;13(10):e18804.
- Mishra Y, Prashar M, Sharma D, Kumar VP, Tilak TV. Diabetes, COVID 19 and mucormycosis: clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr. 2021;15(4):102196.
- Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26.
- Skiada A, Pagano LI, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–67.
- Alqarihi A, Kontoyiannis DP, Ibrahim AS. Mucormycosis in 2023: an update on pathogenesis and management. Front Cell Infect Microbiol. 2023;13:1254919.
- Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–69.
- Vitale RG, De Hoog GS, Schwarz P, Dannaoui E, Deng S, Machouart M, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol. 2012;50(1):66–75.
- Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther. 2021;10(1):115–47.
- Gomez-Lopez A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect. 2020;26(11):1481–7.
- Pastor FJ, Ruiz-Cendoya M, Pujol I, Mayayo E, Sutton DA, Guarro J. In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. Antimicrob Agents Chemother. 2010;54(11):4550–5.
- van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61–
- Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46(7):2310–2.